Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, March 25 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)'. The following are the other relevant details related to the trial:

Therapeutic Area: Respiratory

Trial Centre(s): National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Low Ting Ting Dr Tan Yi Hern

Published by HT Digital Content Services with permission from Health Daily Digest....